Combined_interferon_alfa_and_doxorubicin_in_the_treatment_of_advanced_cervical_cancer._Interferon_alfa_and_doxorubicin_have_been_shown_to_have_synergistic_effects_when_tested_in_vitro_with_cells_derived_from_cervical_cancers._A_clinical_trial_was_designed,_testing_interferon_alfa_plus_doxorubicin_in_patients_with_advanced_or_recurrent_cervical_cancers._Twenty-one_patients_were_given_interferon_alfa,_10_million_units_per_square_meter_intramuscularly_and_10_million_units_per_square_meter_intravenously_over_a_30-minute_infusion_period._One_hour_later_20_mg/m2_doxorubicin_was_given_intravenously_slowly_over_a_2-hour_period._Treatments_were_repeated_once_weekly_for_3_weeks._Initial_response_evaluation_was_done_at_week_5,_and_treatment_was_continued_on_an_every-other-week_schedule_for_patients_showing_favorable_responses_or_stable_disease._Bone_marrow,_hepatic,_and_renal_toxicities_were_minimal._Fever_and_malaise_were_the_major_sources_of_toxicity._Of_the_17_evaluable_patients,_six_had_clinical_partial_responses._Two_of_the_responders_have_enjoyed_more_than_5_years'_survival._This_regimen_is_well_tolerated_and_does_have_efficacy_in_some_patients_with_advanced_cervical_cancers.